Achieve Life Sciences (ACHV) Stock Price, News & Analysis

Company Overview

Achieve Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing cytisinicline, a plant-based investigational therapy intended to help adults quit smoking and address nicotine addiction. Cytisinicline is designed to act on nicotinic acetylcholine receptors in the brain, potentially reducing nicotine cravings and withdrawal symptoms while helping limit the satisfaction associated with smoking.

The company’s primary development program is aimed at securing regulatory approval for cytisinicline in the United States. Achieve has evaluated the therapy in clinical studies involving adults who smoke cigarettes and has also investigated its potential use in helping people quit vaping or using other nicotine products. Cytisinicline has a history of use in certain countries outside the United States under different brand names, although Achieve is conducting its own clinical and regulatory development program for the U.S. market.

Achieve Life Sciences is headquartered in Seattle, Washington, and its operations are centered on clinical development, regulatory activities and commercialization planning for cytisinicline. The company’s leadership includes Chief Executive Officer Rick Stewart, who has experience in the development and commercialization of pharmaceutical products.

Key Stats

• Today's Range: $7.14 to $7.48
• 50-Day Range: $6.32 to $8.53
• 52-Week Range: $2.62 to $8.64
• Volume: 986,731 shs
• Average Volume: 1.51 million shs
• Market Capitalization: $762.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.50
• Consensus Rating: Buy

Achieve Life Sciences Stock Analysis - MarketRank™

Achieve Life Sciences scored higher than 54% of companies evaluated by MarketBeat, and ranked 358th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Achieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Achieve Life Sciences has a consensus price target of $15.50, representing about 109.2% upside from its current price of $7.41.

Amount of Analyst Coverage

Achieve Life Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($0.92) to ($0.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Achieve Life Sciences is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Achieve Life Sciences is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Achieve Life Sciences has a P/B Ratio of 18.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.29% of the float of Achieve Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Achieve Life Sciences has a short interest ratio ("days to cover") of 10.88, which indicates bearish sentiment.

Change versus previous month

Short interest in Achieve Life Sciences has recently increased by 9.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Achieve Life Sciences does not currently pay a dividend.

Dividend Growth

Achieve Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.61

News Sentiment

Achieve Life Sciences has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Achieve Life Sciences this week, compared to 4 articles on an average week.

Search Interest

Only 7 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.

MarketBeat Follows

6 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Achieve Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $175,115.00 in company stock.

Percentage Held by Insiders

1.80% of the stock of Achieve Life Sciences is held by insiders.

Percentage Held by Institutions

33.52% of the stock of Achieve Life Sciences is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ACHV
• CIK: 949858
• Web: achievelifesciences.com
• Phone: (425) 686-1500
• Fax: 425-686-1600
• Employees: 28
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Achieve Life Sciences: $15.50
• High Price Target: $19.00
• Low Price Target: $12.00
• Potential Upside/Downside: +109.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$54.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -511.12%
• Return on Assets: -82.35%

Debt

• Debt-to-Equity Ratio: 0.87
• Current Ratio: 0.95
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.40 per share
• Price / Book: 18.53

Miscellaneous

• Outstanding Shares: 102,900,000
• Free Float: 101,050,000
• Market Cap: $762.49 million
• Optionable: Optionable
• Beta: 2.30